Envisagenics
Envisagenics is a biotechnology company that specializes in developing RNA therapeutics using its AI-driven platform, SpliceCore, which identifies and validates drug targets with a high experimental validation rate.
Services
Envisagenics specializes in the development of RNA therapeutics using advanced Artificial Intelligence (AI) and Machine Learning (ML) technologies. The company offers a software platform called SpliceCore, which leverages RNA sequencing data alongside AI/ML algorithms to identify, test, and validate drug targets. Through this approach, Envisagenics is able to discover novel targets for RNA therapeutics, significantly enhancing the drug development process.
SpliceCore Platform
The SpliceCore platform by Envisagenics stands out with its capabilities in processing vast amounts of RNA sequencing data. SpliceCore boasts a 250x larger search space for target discovery compared to traditional methods, and it maintains a 78% experimental validation rate for discovered targets. This platform is critical for identifying novel drug targets in RNA therapeutics, streamlining the discovery and validation process.
SpliceIOTM Features
SpliceIOTM, an essential feature of the SpliceCore platform, focuses on identifying tumor-specific neoepitopes that are targetable with antibody-based modalities. This innovative approach allows for the development of personalized cancer treatments, specifically targeting unique markers present in individual tumors. The capability of SpliceIOTM to pinpoint these neoepitopes is beneficial for advancing oncology therapies.
Research Collaborations
Envisagenics is actively involved in several strategic research collaborations to advance its RNA therapeutics capabilities. It has agreements with Cancer Research Horizons and Queen Mary University of London focusing on hematopoietic cancers. Additionally, Envisagenics has announced a research collaboration with Bristol Myers Squibb to leverage the SpliceCore AI platform for developing oncology therapeutic candidates. These partnerships underscore Envisagenics' commitment to leveraging cutting-edge technology and collaborative efforts in the field of RNA therapeutics.